Table 4.
Cancer-specific survival in progressive and de novo MIBC patients.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| (A) Progressive MIBC | ||||
| CALD1 | 2.62 (0.99–6.93) | 0.044 | 6.24 (1.37–28.40) | 0.018* |
| Pathological stage | 1.43 (0.98–2.09) | 0.049 | - | 0.060 |
| (B) De novo MIBC | ||||
| CALD1 | 2.40 (1.01–5.73) | 0.048 | – | 0.738 |
| LCOR | 3.16 (1.30–7.66) | 0.011 | 6.75 (2.03–22.42) | 0.002* |
| ITGA5 | 2.55 (1.09–5.99) | 0.031 | – | 0.206 |
| DSC3 | 0.23 (0.08–0.64) | 0.005 | – | 0.371 |
| MSI1 | 3.19 (1.04–9.78) | 0.042 | – | 0.355 |
HR Hazard ratio, CI confidence interval.
*Statistically significant values are in bold..